Limei Hu
YOU?
Author Swipe
View article: Mechanistic evaluation of a traditional herbal decoction in attenuating hepatic fibrosis via Nrf2/GPX4 pathway activation and ferroptosis inhibition
Mechanistic evaluation of a traditional herbal decoction in attenuating hepatic fibrosis via Nrf2/GPX4 pathway activation and ferroptosis inhibition Open
View article: GRICP: Granular-Ball Iterative Closest Point with Multikernel Correntropy for Point Cloud Fine Registration
GRICP: Granular-Ball Iterative Closest Point with Multikernel Correntropy for Point Cloud Fine Registration Open
The Iterative Closest Point (ICP) algorithm suffers from sensitivity to outliers and tendency to local optima in point cloud fine registration. In this paper, we introduce a global and robust ICP framework called Granular-Ball Iterative Cl…
View article: Research on the Collaborative Construction of Ideological and Political Education in Curriculum between Schools and Enterprises from the Perspective of Industry-Education Integration
Research on the Collaborative Construction of Ideological and Political Education in Curriculum between Schools and Enterprises from the Perspective of Industry-Education Integration Open
Industry-education integration is an inevitable trend in the development of vocational education and serves as a crucial pathway for vocational institutions to cultivate students’ practical skills and professional qualities. The constructi…
View article: Survey Bias in Sampling François's Langur in Karst Mountains: An Unmanned Aerial Vehicle (Uav) and Accessibility Perspective
Survey Bias in Sampling François's Langur in Karst Mountains: An Unmanned Aerial Vehicle (Uav) and Accessibility Perspective Open
View article: Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC
Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC Open
The aim of this study was to analyze dihydrolipoyllysine-residue acetyltransferase (DLAT) expression and diagnostic ability in hepatocellular carcinoma (HCC), assess its role in HCC growth, and factors affecting it. We conducted bioinforma…
View article: Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I
Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I Open
This study reveals a previously unknown role of nilotinib in antitumor immunity by inducing MHC-I expression in CRC cells. Our findings suggest that combining nilotinib with anti-PDL1 therapy may be an effective strategy for the treatment …
View article: HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, −10 and −11
HIF-1α Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, −10 and −11 Open
Uncertainty exists regarding the mechanisms by which hypoxia-inducible factors (HIFs) control CD8+T-cell migration into tumor microenvironments. Here, we found that HIF-1α knockdown or overexpression resulted in increased or dec…
View article: Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib
Regarding the prognostic factors in patients with ALK-positive non-small cell lung cancer treated with crizotinib Open
View article: The role of surgical navigation in computer-assisted mandibular reconstruction: is it necessary?
The role of surgical navigation in computer-assisted mandibular reconstruction: is it necessary? Open
Accurate mandibular reconstruction following tumor resection can be achieved by incorporating intraoperative navigation and adjunctive methods such as computer-assisted techniques and our innovative device, mandibular fixation device.
View article: Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins
Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins Open
View article: Supplementary Table 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplementary Table 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Relationship of expression of nuclear p65, E-cadherin, and vimentin with lymph node metastasis in surgical PDAC specimens
View article: Supplementary Table 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplementary Table 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Antibodies, siRNAs, and primers used in this study
View article: Supplemental figure legends from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplemental figure legends from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
legends for supplemental figures.
View article: SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Expression of IGFBP1, IGFBP3, IGFBP4, and IGFBP5 in tumors from PDAC patients and relationship of IGFBP3 and IGFBP5 expression to patient survival.
View article: SUPPLEMENTARY figure 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Expression of IGFBP2 in cell lines, tumors from orthotopic mouse models, and clinical samples.
View article: Supplementary Table 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplementary Table 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Antibodies, siRNAs, and primers used in this study
View article: SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Quantification of western blotting from main Figure 6 and the mRNA levels of PTEN.
View article: SUPPLEMENTARY figure 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Quantification of western blotting results from main Figures 2, 3, and 4.
View article: SUPPLEMENTARY figure 5 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 5 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Quantification of western blotting from main Figure 5.
View article: SUPPLEMENTARY figure 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Morphologic and motility changes in IGFBP2-overexpressing and -knockdown PDAC cells.
View article: SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 7 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Expression of IGFBP1, IGFBP3, IGFBP4, and IGFBP5 in tumors from PDAC patients and relationship of IGFBP3 and IGFBP5 expression to patient survival.
View article: SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Quantification of western blotting from main Figure 6 and the mRNA levels of PTEN.
View article: Supplemental figure legends from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplemental figure legends from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
legends for supplemental figures.
View article: Supplementary Table 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplementary Table 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Relationship of expression of nuclear p65, E-cadherin, and vimentin with lymph node metastasis in surgical PDAC specimens
View article: SUPPLEMENTARY figure 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 1 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Expression of IGFBP2 in cell lines, tumors from orthotopic mouse models, and clinical samples.
View article: SUPPLEMENTARY figure 4 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 4 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
The role of Akt in IGFBP2-mediated IKKβ activation.
View article: Data from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Data from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
The molecular basis underlying the particularly aggressive nature of pancreatic ductal adenocarcinoma (PDAC) still remains unclear. Here we report evidence that the insulin-like growth factor–binding protein IGFBP2 acts as a potent oncogen…
View article: SUPPLEMENTARY figure 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 3 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Quantification of western blotting results from main Figures 2, 3, and 4.
View article: Supplementary Table 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
Supplementary Table 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Correlation of tumor IGFBP2 expression with clinicopathologic characteristics of 80 patients with PDAC
View article: SUPPLEMENTARY figure 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma
SUPPLEMENTARY figure 2 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma Open
Morphologic and motility changes in IGFBP2-overexpressing and -knockdown PDAC cells.